Aytu Bioscience Inc (NASDAQ: AYTU) is making a run for the top early on in the trading session this morning, and for good reason. The company announced the publication of data, highlighting improved efficacy of Natesto over topical gels.
Of course, the news excited investors who are pushing the stock on a run for the top. Today, we’ll talk about:
- The data publication;
- what we’re seeing from AYTU stock as a result; and
- what we’ll be watching for ahead.
AYTU Announces Data Publication
As mentioned above, Aytu BioScience is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the publication of findings from a Phase 4 trial of Natesto.
The trial, known as the My-T study was the first trial documenting that patients’ hypogonadal symptoms improved after switching to Natesto frrom a topical testosterone gel. The results also confirmed that the majority of patients prefer natesto and had higher levels of treatment satisfaction.
In the release, AYTU said that two manuscripts were recently published, highlighting this data. Both of these were published in the Canadian Urologic Association Journal and the second
In the publications, the MY-T study’s authors concluded the following about Natesto by AYTU:
For patients switching from a topical medication to [Natesto] testosterone nasal gel (TNG), effectiveness, convenience and symptoms all demonstrated significant improvements indicating that the divided dose, ultradian profile with TNG is at least, and possibly more, efficacious than the steady state profile provided by topical testosterone. When followed-up 30 days post-treatment, the majority of patients in this study reported having made the switch to TNG as their preferred choice of medication for testosterone replacement.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Aytu Bioscience, the news proved to be overwhelmingly positive.
With the strong data showing that patients prefer Natesto, we can expect that commercialization will continue to head in the right direction. So, it’s not surprising to see that excited investors are pushing the stock up.
As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:23), AYTU is trading at $2.03 per share after a gain of $0.31 per share or 18.03% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on AYTU. In particular, we’re interested in following the company’s continued work to bring Natesto to patients in need as well as the work to expand, develop and commercialize its strong pipeline of products. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!